Filed by Discovery Partners International, Inc. Pursuant to Rule 425

Under the Securities Act of 1933

and Deemed Filed Pursuant to Rule 14a-12

Under the Securities Exchange Act of 1934

Subject Company: Infinity Pharmaceuticals, Inc.

 

This filing relates to the Agreement and Plan of Merger and Reorganization, dated as of April 11, 2006 (the “Merger Agreement”), by and among Discovery Partners International, Inc. (“DPI”), Darwin Corp. and Infinity Pharmaceuticals, Inc. (“Infinity”). The Merger Agreement was attached as Exhibit 1.1 to a Form 8-K filed by DPI with the SEC on April 12, 2006, and is incorporated by reference into this filing.

 

DPI and Infinity gave the following presentation in Boston, Massachusetts on April 26, 2006.

 



 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

 

Link to searchable text of slide shown above


 


 

Searchable text section of graphics shown above

 



 

[LOGO]

 

[GRAPHIC]

 

Reverse Merger Proposal

 

Infinity Pharmaceuticals
and

Discovery Partners International
(Nasdaq: DPII)

 

April 26, 2006

 



 

Michael C. Venuti, Ph.D.

 

Acting Chief Executive Officer

 

Discovery Partners International

 

(Nasdaq:DPII)

 

[LOGO]

 

2



 

Forward-Looking Statement

 

                  This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the proposed transaction, Discovery Partner International’s (DPI) and the combined company’s net cash at closing, the trading of the combined company’s shares on the NASDAQ National Market, the potential value created by the proposed merger for DPI’s and Infinity’s stockholders, DPI’s deployment of its resources and ability to engage in strategic transactions or divest its various business units, the efficacy, safety, and intended utilization of Infinity’s product candidates, the conduct and results of discovery efforts and clinical trials, and plans regarding regulatory filings, future research and clinical trials and plans regarding current and future collaborative activities. Factors that may cause actual results to differ materially include the risk that DPI and Infinity may not be able to complete the proposed transaction, the risk that Infinity’s product candidates and compounds that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in clinical trials, the risks associated with reliance on collaborative partners for further clinical trials and other development activities, risks involved with development and commercialization of product candidates, the risk that DPI may be unable to divest itself of or otherwise transfer ownership of some or all of its business units on satisfactory terms or at all, the risk that DPI’s net cash at closing will be lower than currently anticipated, and risks and other uncertainties more fully described in DPI’s annual report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission and DPI’s other SEC reports. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. The transaction is subject to customary closing conditions, including approval of DPI’s and Infinity’s stockholders.

 

                  Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. DPI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

3



 

Who we are

 

                  Discovery Partners (Nasdaq: DPII)

 

                  Fee-for-service discovery research: chemistry, biology

 

                  Pharma and biotech customers

 

                  Public company since 2000

 

                  $80 million in cash, no debt

 

4



 

Why Merge?

 

DPI rationale

 

                  Response to dramatic changes in discovery business

 

                  Outsourcing to India, China

 

                  Price pressures

 

                  Better upside for investors in near-term product opportunities with significant potential

 

5



 

Why Infinity?

 

Thorough evaluation

 

                  Top-tier private company

 

                  Multiple near-term value driving events

 

                  Ongoing clinical trials

 

                  Pipeline

 

                  Partnerships

 

                  Management that has discovered drugs and built companies

 

                  Create a security with market-recognized value

 

6



 

Steven Holtzman

 

Chairman, Chief Executive Officer

 

Infinity Pharmaceuticals

 

7



 

Why Merge?

 

Infinity rationale

 

                  Cost-effective, timely access to capital

 

                  Clinical trial / preclinical pipeline funding

 

                  Generate efficacy data on lead product candidate, IPI-504

 

                  Accelerate and expand Infinity pipeline

 

8



 

Snapshot of Post-Merger Infinity

 

                  Lead clinical product in two ongoing Phase 1 cancer studies

 

                  Phase 2 expected in 2006

 

                  Pipeline of preclinical cancer drug candidates

 

                  Internally discovered and developed, chemistry platform

 

                  4 Pharma/Biotech corporate alliances

 

                  Amgen, J & J and Novartis (2)

 

                  Cash pro forma Q1: $100 million

 

                  Proven biotech leadership

 

9



 

“Making Cancer a Chronic Disease”

 

Strategy

 

                  Drug targets that are “well-credentialed, but not well-trodden”

 

                  First- or best-in-class medicines

 

                  Fastest path to registration

 

                  Selective strategic alliances to maximize value, retaining significant product rights

 

                  Leverage Infinity’s small molecule technologies

 

                  A culture and community maximally conducive to innovation

 

10



 

Product Pipeline: One IND Filing per Year

 

 

 

Discovery

 

Preclinical

 

IND Filing

 

Clinical Trials

 

 

 

 

 

IPI-504
(Hsp90)

 

 

2005

 

Phase I ongoing
Phase II 2H/2006

 

 

 

 

 

 

 

IPI-609
(Hedgehog)

 

 

2006

 

 

 

 

 

 

 

 

 

Bcl2/Bcl-xL

 

 

2007

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional
Targets

 

 

2008

forward

 

11



 

Product Pipeline: One IND Filing per Year

 

 

 

Discovery

 

Preclinical

 

IND Filing

 

Clinical Trials

 

 

 

 

 

IPI-504
(Hsp90)

 

 

2005

 

Phase I ongoing
Phase II 2H/2006

 

 

 

 

 

 

 

IPI-609
(Hedgehog)

 

 

2006

 

 

 

 

 

 

 

 

 

Bcl2/Bcl-xL

 

 

2007

 

 

 

 

 

 

 

 

 

Additional
Targets

 

 

2008

forward

 

12



 

Lead Clinical Product: IPI-504

 

Best-in-class Hsp90 Inhibitor

 

[GRAPHIC]

 

                  Broad activity, multiple cancers

 

                  Large therapeutic window

 

                  Single agent activity

 

                  Synergy in combination

 

                  Activity in resistant settings

 

                  2nd generation oral formulation under development

 

13



 

IPI-504: Broad Market Potential

 

 

 

Indications

 

 

 

 

 

Multiple Myeloma (MM)

Hematologic
Malignancies

 

 

 

Chronic Myelogenous Leukemia (CML)

 

 

 

 

Acute Myelogenous Leukemia (AML)

 

 

 

 

 

Non-Hodgkin’s Lymphoma (NHL)

 

 

 

 

 

Gastrointestinal Stromal Tumors (GIST)

 

 

 

 

 

Breast cancer (HER2+)

 

 

 

Solid
tumors

 

Non-small cell lung cancer (NSCLC)

 

 

 

Renal cell carcinoma

 

 

 

 

 

Malignant Melanoma

 

 

 

 

 

Hormone Refractory Prostate cancer (HRPC)

 

14



 

IPI-504: Clinical Plan

 

Phase 1

 

                  Multiple myeloma

 

                  GIST

 

                  Combinations

 

Phase 2

 

                  MM / GIST

 

                  Other indications

 

[CHART]

 

15



 

Heat Shock Protein 90 (Hsp90)

 

Emerging cancer target

 

                  Stabilizes proteins in functional conformations

 

                  Two roles in cancer

 

                  Generally: Maintaining protein homeostasis in cancer cells

 

                  Specifically: Stabilization of key oncoproteins, including drug-resistant ones

 

[GRAPHIC]

 

16



 

Targeted Cancer Therapies

 

New Frontier

 

 

 

Molecular Target

 

Targeted therapy

 

Indication

 

 

 

 

 

 

 

 

 

Hematologic

 

NF-kB

 

Velcade

 

Myeloma

 

 

 

Bcr-Abl

 

Gleevec / Dasatinib

 

CML

 

 

 

Flt3

 

Investigational

 

AML

 

 

 

 

 

 

 

 

 

Solid tumor

 

c-Kit

 

Gleevec / Sutent

 

GIST

 

 

 

HER2

 

Herceptin

 

Breast (HER2+)

 

 

 

EGFR

 

Tarceva / Erbitux

 

NSCLC

 

 

 

VEGFR / HIF-1a

 

Sorafenib / Sutent

 

Renal cell

 

 

 

b-Raf

 

Sorafenib

 

Melanoma

 

 

 

p-Akt

 

Investigational

 

Prostate (PTEN -/-)

 

 

17



 

 

 

Molecular Target

 

 

 

 

 

 

 

 

 

Hematologic

 

NF-KB

 

 

 

 

 

Bcr-Abl

 

All are Hsp90 clients

 

 

 

Flt3

 

 

 

 

 

 

 

 

 

Solid tumor

 

c-Kit

 

 

 

 

 

HER2

 

 

 

 

 

EGFR

 

Inhibiting Hsp90 affects the

 

 

 

VEGFR / HIF-1a

 

stability of these targets

 

 

 

b-Raf

 

 

 

 

 

p-Akt

 

 

 

 

18



 

Hsp90: Potential Universal Salvage Therapy

 

Disease

 

Hsp90 Client

 

Drug

 

Kinase
Inhibitor
Resistance
Mutation

 

 

 

 

 

 

 

 

 

 

 

CML

 

BCR-ABL

 

Gleevec, Dasatinib

 

T315I

 

Highly responsive to Hsp90 inhibition

 

 

 

 

 

 

 

 

 

GIST

 

KIT

 

Gleevec, Sutent

 

T670I

 

 

 

 

 

 

 

 

 

 

 

NSCLC

 

EGFR

 

Iressa, Tarceva

 

T790M

 

Alternative to chasing mutations

 

19



 

Oral IPI-504: Survival Benefit

 

Gleevec-resistant T315I

CML transplantation model

 

[CHART]

 

Collaboration:

Shauguang Li, Jackson Labs

 

20



 

[CHART]

 

21



 

[CHART]

 

22



 

IPI-504: Clinical Milestones for 2006

 

                  Phase 1 MM trials: complete

 

                  Phase 1 GIST trial: complete

 

                  Phase 2 MM and/or GIST trial: initiate

 

Additional potential indications and milestone events

 

                  Phase 1 combination studies (e.g. Taxotere, Velcade, Gleevec)

 

                  Additional Phase 2 studies (e.g. NSCLC, CML, CLL)

 

23



 

Product Pipeline: One IND Filing per Year

 

 

 

Discovery

 

Preclinical

 

IND Filing

 

Clinical Trials

 

 

 

 

 

IPI-504
(Hsp90)

 

 

2005

 

Phase I ongoing
Phase II 2H/2006

 

 

 

 

 

 

 

IPI-609
(Hedgehog)

 

 

2006

 

 

 

 

 

 

 

 

 

Bcl2/Bcl-xL

 

 

2007

 

 

 

 

 

 

 

 

 

Additional
Targets

 

 

2008

forward

 

24



 

IPI-609: Most Advanced Preclinical Candidate

 

Potent hedgehog pathway inhibitor

 

                  Expected first-in-class systemic hedgehog inhibitor

 

                  Proprietary NCE

 

                  Oral product

 

                  Broad anti-cancer potential

 

                  Strong data supporting pancreatic, metastatic prostate, SCLC, others

 

                  Single agent activity

 

                  Potential for synergy with standards of care

 

25



 

IPI-609: Clinical Plan

 

2005

 

2006

 

2007

 

2008

 

 

 

 

 

 

 

 

 

IND-enabling studies

 

FILE IND

 

Clinical development

 

 

 

 

 

 

 

 

 

 

 

 

 

Phase I

 

Phase II

 

Pharmacology
GLP toxicology
Manufacturing

 

 

 

Pancreatic
SCLC
Met Prostate, etc.
Heme malignancies

 

Single or combo

 

 

 

 

 

 

 

 

Phase II or III
Registration trial

 

 

26



 

IPI-609: Preclinical Efficacy Rationale

 

PC3 prostate cancer xenograft

 

[CHART]

 

27



 

Hedgehog Pathway: Broad Rationale in Solid Tumors

 

Human tumor biopsy data

 

State

 

Pathway activation

 

Normal

 

OFF

 

Basal cell carcinoma(1),(2)

 

ON

 

Medulloblastoma(3)

 

ON

 

Pancreatic cancer(4),(5),(6)

 

ON

 

Prostate cancer(7),(8)

 

ON

 

Small cell lung cancer(9)

 

ON

 

Hepatocellular cancer(10)

 

ON

 

Breast Cancer(11)

 

ON

 

 


(1) Hahn et al., 1996, Cell 85: 841

(2) Bale & Yu, 2001, Human Molec. Genetic. 10: 757 (review)

(3) Berman et al., 2002 Science 297: 1559

(4) Berman et al., 2003 Nature 425: 846

(5) Kayed et al., 2004 Int. J. Cancer 110: 668

(6) Thayer et al., 2003 Nature 425: 851

(7) Karhadkar et al., 2004 Nature, 431: 707

(8) Fan et al., 2004 Endocrinology 145: 3961

(9) Watkins et al., 2003, Nature 422: 313

(10) Sicklick  2005 ASCO; Mohini, 2005 AACR

(11) Kubo et al., 2004 Cancer Res. 64 :6071

 

28



 

Product Pipeline: One IND Filing per Year

 

 

 

Discovery

 

Preclinical

 

IND Filing

 

Clinical Trials

 

 

 

 

 

IPI-504
(Hsp90)

 

 

2005

 

Phase I ongoing
Phase II 2H/2006

 

 

 

 

 

 

 

IPI-609
(Hedgehog)

 

 

2006

 

 

 

 

 

 

 

 

 

Bcl2/Bcl-xL

 

 

2007

 

 

 

 

 

 

 

 

 

Additional
Targets

 

 

2008

forward

 

29



 

Bcl-2 / Bcl-xL Antagonists: Opportunities

 

Therapeutic Applications

 

                  Bcl key anti-apoptotic factors

 

                  Up-regulated in many cancers

 

                  Up-regulated in response to chemotherapy in many cancers

 

                  Highly attractive but historically “intractable”

 

                  Protein-protein interaction targets

 

                  Prospective products

 

                  Combination with chemotherapy: general chemo-sensitizing agent

 

                  Single agent: in cancers dependent on Bcl family members for survival

 

                  Types of products:

 

                  Bcl-2 selective

 

                  Bcl-2 and Bcl-xL dual selective

 

30



 

Bcl: Lead Compounds from DOS

 

Infinity’s Small Molecule Technology

 

Product
profile

 

Bcl-2

 

Bcl-xL

 

 

 

 

 

(Ki)

 

(Ki)

 

 

 

 

 

 

 

 

 

 

 

Bcl-2

 

 

 

 

 

>1,000x

 

Selective

 

65 pM

 

100 nM

 

selectivity

 

 

 

 

 

 

 

 

 

Dual selective

 

1.1 nM

 

6 nM

 

 

 

 

31



 

Bcl:  2006 Novartis Alliance

 

ACTIVITIES

 

FINANCIALS

 

 

 

 

 

                  Joint discovery (led by Infinity)

 

                  Upfront & near term committed

$30M

 

 

 

 

 

 

                  Joint development (led by Novartis)

 

                  Total potential payments

>$400M

 

 

 

 

 

                  Worldwide marketing by Novartis with Infinity US co-promotion

 

                  Royalties on WW sales

 

 

Accelerates, expands value creation

 

32



 

DOS Technology Alliances: Small Molecules

 

[LOGO]

 

[LOGO]

 

[LOGO]

 

                  Diversity Oriented Synthesis (DOS)

 

                  2004 – 2006:   > $60 million upfront/committed cash

 

                  Non-dilutive capital and capability expansion

 

                  Additional milestone and royalty potential

 

                  No license of proprietary Infinity product rights

 

[GRAPHIC]

 

[GRAPHIC]

 

[GRAPHIC]

 

33



 

Pipeline & Partnerships

 

Ownership of most advanced candidates retained

 

 

 

Discovery

 

Preclinical

 

IND Filing

 

 

 

 

 

 

 

 

 

 

 

 

 

IPI-504
(Hsp90)

 

 

2005

 

100% owned

 

 

 

 

 

 

 

 

 

 

 

IPI-609
(Hedgehog)

 

 

2006

 

100% owned

 

 

 

 

 

 

 

 

 

 

 

Bcl2/Bcl-xL

 

 

2007

 

Novartis

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-exclusive

 

 

 

                  Amgen

 

Small molecule drug technologies

 

                  Novartis

 

 

 

                  J&J

 

 

34



 

Leadership: Combined Company

 

Mr. Steven Holtzman, Chairman & CEO
Millennium, DNX

 

Dr. Julian Adams, President & CSO
Millennium, ProScript

Boehringer Ingelheim, Merck

 

Ms. Adelene Perkins, EVP & CBO
Transform, Genetics Institute,
Bain, GE

 

Dr. Christine Bellon, Sr Patent Counsel
Wyeth, Fish & Richardson

 

Dr. Michael Foley, VP Chemistry
Harvard ICCB, Glaxo, BMS

 

Dr. Christian Fritz, Sr Dir Cancer Biology
Millennium, Chemgenix

 

Dr. David Grayzel, VP Clinical Dev/Med Affairs
Dyax, Mass General Hospital

 

Dr. Vito Palombella, VP Biology
Syntonix, Millennium
, ProScript

 

Dr. Margaret Read, Sr Dir Cancer Biology
Millennium, ProScript

 

Dr. Jeffrey Tong, VP Corp & Product Dev
McKinsey & Co, Harvard Center for Genomics Research

 

Dr. Jim Wright, VP Pharm Dev
Millennium, Alkermes, Boehringer Ingelheim, U. of Wisconsin

 

35



 

Projected Board of Directors: Combined Company

 

Steven Holtzman, Chairman

 

Infinity Pharmaceuticals, Inc

 

 

 

 

 

Ron Daniel

 

McKinsey & Co. (former Managing Partner)

 

 

 

 

 

Dr. Tony Evnin

 

Venrock Associates

 

 

 

 

 

Dr. Eric Lander

 

Director Broad Institute, Whitehead, MIT

 

 

 

 

 

Patrick Lee

 

Advent Venture Partners

 

 

 

 

 

Dr. Arnold Levine

 

Institute for Advance Study

 

 

 

 

 

Dr. Frank Moss

 

Director MIT Media Lab; Founding CEO Tivoli

 

 

 

 

 

Dr. Vicki Sato

 

Former Vertex and Biogen

 

 

 

 

 

Dr. James Tananbaum

 

Prospect Venture Partners

 

 

 

 

 

Dr. Michael Venuti

 

Discovery Partners, Celera

 

 

 

 

 

Mr. Harry Hixon

 

BrainCells, Amgen

 

 

 

 

 

Mr. Herm Rosenman

 

Gen-Probe

 

 

36



 

Infinity’s Financial and Pharmaceutical Investors

 

                  Prospect Venture Partners

 

                  Venrock Associates

 

                  Advent Venture Partners

 

                  HBM BioVentures

 

                  Vulcan Ventures

 

                  Wellcome Trust

 

                  POSCO BioVentures

 

                  Tallwood

 

                  Alexandria Equities

 

                  Lotus BioScience

 

                  Amgen

 

                  Novartis

 

                  J&J

 

37



 

The Merger: Next Steps

 

38



 

Key Merger Terms

 

                  A financing event

 

                  DPI “invests” cash and divests operating units

 

                  If DPI cash between $70M and $75M, ownership:

 

                  DPI shareholders = 31%

 

                  Infinity shareholders = 69%

 

                  If cash above $75M or below $70M, adjustment applied

 

39



 

Merger Timetable

 

Approval of both companies’ BOD

 

ý

 

 

 

 

 

Public announcement of transaction

 

ý

 

 

 

 

 

File S-4

 

By Mid-May

 

 

 

 

 

SEC comment period

 

By Late June

 

 

 

 

 

Joint proxy statement / prospectus to DPI, Infinity stockholders

 

By Mid-July

 

 

 

 

 

DPI, Infinity Stockholder votes

 

By Mid-August

 

 

 

 

 

If approved
DPI shares issued
Infinity traded as public company

 

Following vote

 

 

40



 

2006 News flow, Milestones and Goals

 

Status

 

                  Product Pipeline

 

 

 

 

 

 

 

                  IPI-504: Complete Phase 1s

 

 

 

 

 

 

 

                  IPI-504: Initiate Phase 2

 

 

 

 

 

 

 

                  IPI-609: File IND

 

 

 

 

 

 

 

                  Pipeline: New INDs / programs for 2007+

 

 

 

 

 

 

 

                  Successful alliance execution (Novartis, J&J, Amgen)

 

 

 

 

 

 

 

                  At least one new corporate alliance

 

ý

 

 

 

 

 

                  Financing event: Approved merger

 

 

 

 

 

 

 

                  Year-end cash runway: > 12-24 months

 

 

 

 

41



 

[LOGO]

 

www.IPI.com

 



 

Forward Looking Statements

 

This filing contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the proposed transaction, DPI’s and the combined company’s net cash at closing, the trading of the combined company’s shares on the NASDAQ National Market, the potential value created by the proposed merger for DPI’s and Infinity’s stockholders, DPI’s deployment of its resources and ability to engage in strategic transactions or divest its various business units, the efficacy, safety, and intended utilization of Infinity’s product candidates, the conduct and results of discovery efforts and clinical trials, and plans regarding regulatory filings, future research and clinical trials and plans regarding current and future collaborative activities. Factors that may cause actual results to differ materially include the risk that DPI and Infinity may not be able to complete the proposed transaction, the risk that Infinity’s product candidates and compounds that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in clinical trials, the risks associated with reliance on collaborative partners for further clinical trials and other development activities, risks involved with development and commercialization of product candidates, the risk that DPI may be unable to divest itself of or otherwise transfer ownership of some or all of its business units on satisfactory terms or at all, the risk that DPI’s net cash at closing will be lower than currently anticipated, and risks and other uncertainties more fully described in DPI’s annual report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission and DPI’s other SEC reports. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. The transaction is subject to customary closing conditions, including approval of DPI’s and Infinity’s stockholders.

 

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. DPI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Additional Information about the Merger and Where to Find It

 

In connection with the proposed transaction described herein, DPI will file a registration statement on Form S-4 that contains a proxy statement/prospectus with the SEC. Investors and security holders of DPI and Infinity are

 



 

urged to read the proxy statement/prospectus (including any amendments or supplements to the proxy statement/prospectus) regarding the proposed transaction when it becomes available because it will contain important information about DPI, Infinity and the proposed transaction. Security holders will be able to obtain a copy of the proxy statement/prospectus, as well as other filings containing information about DPI and Infinity, without charge, at the SEC’s Internet site (http://www.sec.gov). Copies of the proxy statement/prospectus and the filings with the SEC that will be incorporated by reference in the proxy statement/prospectus, if any, can also be obtained, without charge, by directing a request to Discovery Partners International, Inc., 9640 Towne Centre Drive, San Diego, CA 92121, Attention: Investor Relations, Telephone: (858) 455-8600.

 

Participants in the Solicitation

 

DPI and its directors and executive officers and Infinity and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of DPI in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger transaction will be included in the proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of DPI is also included in DPI’s proxy statement for its 2006 Annual Meeting of Stockholders, which was filed with the SEC on April 6, 2006. This document is available free of charge at the SEC’s web site (www.sec.gov) and from Investor Relations at DPI at the address described above.